AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase 3 study titled ‘A Multicentre, Randomised, Double-Blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus.’ The study aims to assess the efficacy and safety of subcutaneous anifrolumab in adults with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard therapy. This research is significant as it could offer a new treatment option for SLE patients.
The study tests anifrolumab, an experimental drug administered via a prefilled syringe, against a placebo. Anifrolumab is intended to improve the condition of patients with SLE by providing an additional treatment option alongside standard care.
This interventional study follows a randomized, parallel assignment model with single masking. The primary purpose is treatment, with participants receiving either the experimental drug or a placebo.
The study began on June 8, 2021, with primary completion expected at Week 52 of the trial. The last update was submitted on August 11, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and anticipated results.
The study’s outcome could significantly impact AstraZeneca’s stock performance by potentially introducing a new treatment to the market, enhancing investor confidence. The competitive landscape in the pharmaceutical industry for SLE treatments could also shift, depending on the study’s results.
The study is ongoing, and further details are available on the ClinicalTrials portal.